[Impact of COVID-19 on ST-segment Elevation Myocardial Infarction Care. The Spanish Experience]
Overview
Authors
Affiliations
Introduction And Objectives: The COVID-19 outbreak has had an unclear impact on the treatment and outcomes of patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to assess changes in STEMI management during the COVID-19 outbreak.
Methods: Using a multicenter, nationwide, retrospective, observational registry of consecutive patients who were managed in 75 specific STEMI care centers in Spain, we compared patient and procedural characteristics and in-hospital outcomes in 2 different cohorts with 30-day follow-up according to whether the patients had been treated before or after COVID-19.
Results: Suspected STEMI patients treated in STEMI networks decreased by 27.6% and patients with confirmed STEMI fell from 1305 to 1009 (22.7%). There were no differences in reperfusion strategy (> 94% treated with primary percutaneous coronary intervention in both cohorts). Patients treated with primary percutaneous coronary intervention during the COVID-19 outbreak had a longer ischemic time (233 [150-375] vs 200 [140-332] minutes, < .001) but showed no differences in the time from first medical contact to reperfusion. In-hospital mortality was higher during COVID-19 (7.5% vs 5.1%; unadjusted OR, 1.50; 95%CI, 1.07-2.11; < .001); this association remained after adjustment for confounders (risk-adjusted OR, 1.88; 95%CI, 1.12-3.14; = .017). In the 2020 cohort, there was a 6.3% incidence of confirmed SARS-CoV-2 infection during hospitalization.
Conclusions: The number of STEMI patients treated during the current COVID-19 outbreak fell vs the previous year and there was an increase in the median time from symptom onset to reperfusion and a significant 2-fold increase in the rate of in-hospital mortality. No changes in reperfusion strategy were detected, with primary percutaneous coronary intervention performed for the vast majority of patients. The co-existence of STEMI and SARS-CoV-2 infection was relatively infrequent.
Carrion Arcela J, Custodio-Sanchez P, Coca Caycho T Arch Peru Cardiol Cir Cardiovasc. 2023; 2(3):159-166.
PMID: 37727520 PMC: 10506557. DOI: 10.47487/apcyccv.v2i3.148.
Gonzalez I, Alonso Valle H, Abejez L, Molas A, Alonso-Molero J, Dierssen-Sotos T Intern Emerg Med. 2023; 18(7):2093-2103.
PMID: 37308693 PMC: 10259810. DOI: 10.1007/s11739-023-03328-2.
Impact of Coronavirus-19 Pandemic and Lockdown on Admissions for Ischemic Heart Disease.
Garcia J, Iturregui Guevara M, Garcia E, Campuzano Ruiz R, Garcia R Cardiol Cardiovasc Med. 2023; 6(4):353-363.
PMID: 36968309 PMC: 10035782. DOI: 10.26502/fccm.92920270.
Lopez-de-Andres A, Jimenez-Garcia R, Carabantes-Alarcon D, Hernandez-Barrera V, de-Miguel-Yanes J, de-Miguel-Diez J Int J Environ Res Public Health. 2023; 20(1).
PMID: 36613166 PMC: 9819421. DOI: 10.3390/ijerph20010844.
Del Cura-Gonzalez I, Polentinos-Castro E, Fontan-Vela M, Lopez-Rodriguez J, Martin-Fernandez J Gac Sanit. 2022; 36 Suppl 1:S36-S43.
PMID: 35781146 PMC: 9244613. DOI: 10.1016/j.gaceta.2022.03.003.